Fluoxetine, topiramate, and combination of both to stabilize eating behavior before bariatric surgery.

INTRODUCTION: Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction (reduction in body fat, risk factors for cardiovascular disease and the incidence of diabetes mellitus). Among drugs that have been evaluated for weight loss include antidepressants (fluoxetine) and antiepileptic (topiramate). MATERIAL AND METHODS: We analyzed eating behavior and weight loss in a sample of morbid obesity patients before bariatric surgery. The patients suffering eating disturbances symptoms were grouped into three groups: one group received 40 mg of flouxetine/day (Group A); another group received topiramate 200 mg/day (Group B); and the third group of patients were treated with fluoxetine 40 mg and 200 mg of topiramate/day (Group C). RESULTS: Patients treated with fluoxetine plus topiramate lost more weight at 3 and 6 months before surgery. CONCLUSIONS: The use of the psychopharmaceutical drug (fluoxetine and topiramate) in morbid obese patients with eating disorders could represent a new approach to the management of eating behavior before bariatric surgery.

Oseltamivir- related psychiatric manifestations.

The importance effect on the population of the new virus Influenza A/H1N1 and the potential therapeutic with Oseltamivir. Clinical case. Patient of 62 years old, without history of interest, contracted Influeza A, that she undergoes a confusional syndrome responding to antipsychotics and with complete recovery after the episode. Conclusions. Establish the possible relationship between the various factors are influencing the onset confusional syndrome in a patient infected with Inluenza A treated with Oseltamivir.

Concurrence of multiples factors in the occurrence of ventricular arrhythmia in patient treated with aripiprazole.

INTRODUCTION: The Importance of the cardiovascular effects, fundamentally the ventricular arrhythmias, produced by the antipsychotic ones, is discussed. CLINICAL CASE: 28 year old patient with morbid obesity, operated by bariatric surgery, with good result, suffers a ventricular no supported polymorphic tachycardia while he was heightening treatment with aripiprazole and fluoxetine. CONCLUSIONS: To value the influence of diverse factors for the production of ventricular arrhythmias emphasizing fundamentally the interactions of aripiprazole and the loss of weight.

[Intracranial sinus thrombosis secondary to the consumption of inhaled speed]. / Trombosis de seno venoso intracraneal secundaria al consumo de speed inhalado.

INTRODUCTION: Speed is a psychostimulant of the Central Nervous System that can cause behavioral alterations, euphoria, psychosis and diverse organic medical pictures. CLINICAL CASE: The case of a 19 year old male patient, who consumes amphetamines, who had behavioral alterations and heteroaggressiveness, circumstances that required psychiatric admission is presented. After performing brain imaging tests, intracranial venous sinus thrombosis was found, which has not, up to the present date, developed significant symptoms. CONCLUSIONS: The aim of the above-mentioned report is to know the mechanism of action of the speed and to relate it consumption to the appearance of intracranial sinus thrombosis. To do so, a search was conducted in the PubMed database using the following terms: amphetamines and intracranial sinus thrombosis; street drugs and cerebrovascular disease; and adverse effects of the drugs.